Meriofert (Follicle-Stimulating Hormone, Luteinising Hormone)

FSH binds to receptors on ovarian granulosa cells, promoting follicular growth and estradiol production. LH binds to receptors on theca and luteal cells, triggering final follicle maturation, ovulation and luteal phase support. Together they replicate the natural pituitary surge that drives normal folliculogenesis and ovulation.

The dose of Meriofert is individualized and determined by the prescribing physician based on the patient’s ovarian reserve, treatment protocol and response to monitoring. Dosing regimens can vary widely, and the prescriber will adjust the amount and frequency to achieve the desired clinical outcome.

Meriofert is not intended for use during an established pregnancy and is contraindicated in pregnant women. Safety data for breastfeeding are limited; therefore, the product should be used with caution, and the prescriber should weigh potential risks against benefits before administering to nursing mothers.

To order Meriofert, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide. After the request, the sales team will verify trade or institutional credentials, then provide pricing, availability, shipping details (including cold‑chain logistics if needed) and any required import documentation.

Meriofert combines both FSH and LH in a single injectable formulation, whereas some alternatives provide only FSH or require separate LH supplementation. The combined product can simplify dosing schedules and may improve follicular response in patients who need both hormones, but the choice depends on individual protocol preferences and physician experience.

Meriofert must be stored at 2‑8 °C (refrigerated). Keep the vial in its original packaging, protect it from light, and avoid freezing or shaking the solution. If temporary temperature excursions occur, discard the product according to local regulations.

Meriofert is supplied as a sterile injectable solution for intramuscular or subcutaneous injection. The injection is performed by a qualified healthcare professional using aseptic technique. The exact injection site, volume and frequency are prescribed by the treating clinician based on the therapeutic protocol.

The most serious risks include severe ovarian hyperstimulation syndrome (OHSS), which can cause abdominal distension, ascites, thromboembolic events, and electrolyte imbalance, as well as rare allergic reactions such as anaphylaxis. Prompt recognition and medical management of these conditions are essential.

Meriofert should not be used in women who are already pregnant, have active ovarian cysts, uncontrolled thyroid disease, or a known hypersensitivity to any component of the formulation. Patients with a personal or strong family history of thromboembolic disorders should be evaluated carefully before treatment.